Abstract
Experimental study of obstetric antiphospholipid syndrome may reduce morbidity and deaths of women and newborns. Aim. The aim of the work is to examine relevant literature on modeling obstetric antiphospholipid syndrome, to choose the most appropriate model and to reproduce it in accordance with existing clinical criteria. The current views on the modeling of disease depending on the purposes, selection of laboratory animals, treatment and dosing medications, evaluation of the effectiveness of simulation and experimental treatment were comprehensively analyzed. Results. According to the authors the most appropriate model is a model of active immunization of mice with the cardiolipin antigen, which was reproduced in the author's modification.
Highlights
Экспериментальное изучение гестационного антифосфолипидного синдрома (АФС) является значительным резервом снижения заболеваемости и смертности женщин и новорожденных
The current views on the modeling of disease depending on the purposes, selection of laboratory animals, treatment and dosing medications, evaluation of the effectiveness of simulation and experimental treatment were comprehensively analyzed
According to the authors the most appropriate model is a model of active immunization of mice with the cardiolipin antigen, which was reproduced in the author’s modification
Summary
Экспериментальное изучение гестационного антифосфолипидного синдрома (АФС) является значительным резервом снижения заболеваемости и смертности женщин и новорожденных. Ризик втрати плода при наступній вагітності у разі відсутності лікування у жінок із гестаційним АФС досягає 80–90%, що становить суттєвий відсоток серед пренатальних втрат [4,7]. Клінічні прояви АФС мають 30–50% людей, у крові яких присутні разом з аФЛ, антикардіоліпінові антитіла (аКЛ) чи вовчаків антикоагулянт (ВА). Для терапії гестаційного АФС застосовують препарати, котрі мають властивості як антикоагулянтів, так і антиагрегантів [6,7,19].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
